Abstract
Curcumin is the main biological active polyphenolic compound present in the rhizomes of turmeric (Curcuma longa Linn.), has a wide biological and pharmacological profile. It has been reported to possess anti-oxidative, anti-inflammatory and anti-carcinogenic properties [1–3]. Many clinical study reports have revealed that curcumin has many beneficial properties in the treatment of various diseases in man such as pancreatic cancer and inflammatory bowel disease [4,5]. Despites these promising effects a poor oral absorption due to its extremely low aqueous solubility and rapid metabolism result in very low oral systemic bioavailability, thus limiting its clinical use. In order to overcome bioavailability drawbacks, this work proposes inclusion of curcumin into liposomal carriers.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
